Table 1

Effects of A1R activation on population burst parameters

Slice

Island



Treatment Group

Stage of Experiment

n

Frequency

(bursts·sec-1)

Amplitude

n

Frequency

(bursts·sec-1)

Amplitude


aCSF control

1. Baseline

12

0.33 ± 0.02

2.01 ± 0.24

9

0.37 ± 0.04

1.39 ± 0.25

2. aCSF

0.33 ± 0.03

2.03 ± 0.25

0.36 ± 0.04

1.50 ± 0.31

3. NCPA

0.24 ± 0.03

2.13 ± 0.24

0.26 ± 0.04a, b

1.57 ± 0.40

4. DPCPX

0.31 ± 0.02

1.81 ± 0.22

0.37 ± 0.03

1.48 ± 0.44

Bicuculline

1. Baseline

11

0.36 ± 0.03

1.65 ± 0.23

7

0.44 ± 0.06

1.13 ± 0.19

2. Bicuculline

0.33 ± 0.02

2.27 ± 0.35a

0.43 ± 0.05

1.77 ± 0.29a

3. NCPA

0.22 ± 0.03a, b

2.33 ± 0.35a

0.41 ± 0.05

1.55 ± 0.21a

4. DPCPX

0.31 ± 0.03

1.93 ± 0.30

0.48 ± 0.07

1.81 ± 0.37a

Gabazine

1. Baseline

7

0.34 ± 0.07

3.10 ± 1.14

6

0.27 ± 0.04

0.89 ± 0.10

2. Gabazine

0.33 ± 0.06

3.48 ± 1.24

0.29 ± 0.03

0.86 ± 0.10

3. NCPA

0.25 ± 0.07a, b

2.56 ± 0.89

0.18 ± 0.05a, b

0.89 ± 0.15

4. DPCPX

0.32 ± 0.06

3.37 ± 1.11

0.30 ± 0.05

0.76 ± 0.09

Gabazine & Strychnine

1. Baseline

8

0.33 ± 0.05

0.97 ± 0.16

6

0.40 ± 0.06

1.15 ± 0.16

2. Gabazine + Strychnine

0.30 ± 0.04

1.40 ± 0.20

0.40 ± 0.05

1.46 ± 0.23a

3. NCPA

0.24 ± 0.03a, b

1.31 ± 0.23

0.34 ± 0.05

1.51 ± 0.26a

4. DPCPX

0.30 ± 0.03

1.10 ± 0.17

0.38 ± 0.04

1.45 ± 0.26a


Slices were superfused with one of four solutions prior to treatment with NCPA (aCSF alone, aCSF with bicuculline, aCSF with gabazine, or aCSF with gabazine and strychnine).

1All values presented as mean ± SEM.

aDifferent from baseline (pre-treatment) value at P < 0.05 (Tukey post-hoc tests)

bDifferent from control (aCSF only) at P < 0.05 (Tukey post-hoc tests)

VanDam et al. BMC Neuroscience 2008 9:95   doi:10.1186/1471-2202-9-95

Open Data